Zobrazeno 1 - 10
of 118
pro vyhledávání: '"Ryo, Ko"'
Autor:
Kosei Doshita, Tateaki Naito, Suguru Matsuda, Meiko Morita, Motoki Sekikawa, Keita Miura, Hiroaki Kodama, Michitoshi Yabe, Noboru Morikawa, Yuko Iida, Nobuaki Mamesaya, Haruki Kobayashi, Ryo Ko, Kazushige Wakuda, Akira Ono, Haruyasu Murakami, Hirotsugu Kenmotsu, Toshiaki Takahashi
Publikováno v:
Thoracic Cancer, Vol 15, Iss 25, Pp 1831-1841 (2024)
Abstract Background Chemotherapy‐induced anorexia is a common occurrence in patients undergoing treatment for advanced lung cancer. However, the relationship between chemotherapy‐induced anorexia and weight loss during platinum‐based chemothera
Externí odkaz:
https://doaj.org/article/1c619e4840f7419cb18ab6e638421ba1
Autor:
Hiroaki Kodama, Haruyasu Murakami, Nobuaki Mamesaya, Haruki Kobayashi, Shota Omori, Kazushige Wakuda, Ryo Ko, Akira Ono, Hirotsugu Kenmotsu, Tateaki Naito, Shingo Matsumoto, Koichi Goto, Tetsuo Shimizu, Yasuhiro Gon, Toshiaki Takahashi
Publikováno v:
Thoracic Cancer, Vol 15, Iss 21, Pp 1665-1672 (2024)
Abstract Background The AmoyDx Pan lung cancer PCR panel (AmoyDx PLC panel) has been approved as a companion diagnostic tool for multiple anticancer agents in patients with non‐small cell lung cancer (NSCLC). However, the suitability of cytology sp
Externí odkaz:
https://doaj.org/article/6c1fe2baa59945ae9b7a90da2d5d7001
Autor:
Meiko Morita, Akira Ono, Motoki Sekikawa, Kosei Doshita, Keita Miura, Hiroaki Kodama, Michitoshi Yabe, Noboru Morikawa, Yuko Iida, Nobuaki Mamesaya, Haruki Kobayashi, Ryo Ko, Kazushige Wakuda, Hirotsugu Kenmotsu, Tateaki Naito, Haruyasu Murakami, Mitsuhiro Isaka, Yasuhisa Ohde, Toshiaki Takahashi
Publikováno v:
Cancer Reports, Vol 7, Iss 9, Pp n/a-n/a (2024)
ABSTRACT Background Mutations in the epidermal growth factor receptor (EGFR) gene are the most common targetable gene alterations in non‐small cell lung cancer (NSCLC). In Japan, approximately 40% of patients who undergo surgical resection for non
Externí odkaz:
https://doaj.org/article/3c7205c59c0848928a7fc40d19564462
Autor:
Yuko Iida, Kazushige Wakuda, Hirotsugu Kenmotsu, Kosei Doshita, Hiroaki Kodama, Naoya Nishioka, Eriko Miyawaki, Taichi Miyawaki, Nobuaki Mamesaya, Haruki Kobayashi, Shota Omori, Ryo Ko, Akira Ono, Tateaki Naito, Haruyasu Murakami, Takashi Sugino, Yasuhiro Gon, Toshiaki Takahashi
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract The efficacy of second-line chemotherapy in patients with pulmonary large cell neuroendocrine carcinoma (LCNEC) is unclear. This study aimed to evaluate the efficacy of second-line chemotherapy in patients with pulmonary LCNEC. We retrospect
Externí odkaz:
https://doaj.org/article/9ca57d0b679e413492866893556df8e6
Autor:
Yuko Iida, Kazushige Wakuda, Takuya Kawata, Meiko Morita, Motoki Sekikawa, Kosei Doshita, Michitoshi Yabe, Hiroaki Kodama, Keita Miura, Noboru Morikawa, Nobuaki Mamesaya, Haruki Kobayashi, Ryo Ko, Akira Ono, Hirotsugu Kenmotsu, Tateaki Naito, Haruyasu Murakami, Yasuhiro Gon, Toshiaki Takahashi
Publikováno v:
Thoracic Cancer, Vol 15, Iss 6, Pp 477-485 (2024)
Abstract Background Which patients benefit from the addition of immune checkpoint inhibitors (ICIs) to chemotherapy for small cell lung cancer (SCLC) remains unclear. There have been few reports on the efficacy of ICIs based on conventional immunohis
Externí odkaz:
https://doaj.org/article/e463e71dc180423c8cb17938224f6040
Autor:
Motoki Sekikawa, Haruyasu Murakami, Meiko Morita, Kosei Doshita, Keita Miura, Hiroaki Kodama, Noboru Morikawa, Yuko Iida, Nobuaki Mamesaya, Haruki Kobayashi, Ryo Ko, Kazushige Wakuda, Akira Ono, Hirotsugu Kenmotsu, Tateaki Naito, Hirofumi Chiba, Toshiaki Takahashi
Publikováno v:
Thoracic Cancer, Vol 14, Iss 35, Pp 3475-3482 (2023)
Abstract Background Amrubicin (AMR) regimens have shown efficacy as second‐line treatment in patients with small cell lung cancer (SCLC); however, adverse events such as febrile neutropenia (FN) sometimes preclude their use. Further, the safety and
Externí odkaz:
https://doaj.org/article/4fa201b940bf4f3497e40475cb88b5de
Autor:
Koichiro Kanamori, Kentaro Suina, Takehito Shukuya, Fumiyuki Takahashi, Takuo Hayashi, Kieko Hara, Tsuyoshi Saito, Yoichiro Mitsuishi, Shoko Sonobe Shimamura, Wira Winardi, Ken Tajima, Ryo Ko, Tomoyasu Mimori, Tetsuhiko Asao, Masayoshi Itoh, Hideya Kawaji, Yoshiyuki Suehara, Kazuya Takamochi, Kenji Suzuki, Kazuhisa Takahashi
Publikováno v:
Thoracic Cancer, Vol 14, Iss 12, Pp 1089-1097 (2023)
Abstract Background Thymic squamous cell carcinoma and type B3 thymoma are primary neoplasms of the anterior mediastinum that are sometimes difficult to differentiate from one another histologically. However, only a few immunohistochemical markers ar
Externí odkaz:
https://doaj.org/article/68cea7b7cfed4f3e8ae2bc5b691dc2fb
Autor:
Nobuaki Mamesaya, Hiroaki Kodama, Yuko Iida, Haruki Kobayashi, Ryo Ko, Kazushige Wakuda, Akira Ono, Hirotsugu Kenmotsu, Tateaki Naito, Haruyasu Murakami, Tetsuo Shimizu, Yasuhiro Gon, Toshiaki Takahashi
Publikováno v:
Thoracic Cancer, Vol 14, Iss 9, Pp 805-814 (2023)
Abstract Carboplatin plus etoposide is a standard treatment for older extensive‐stage small‐cell lung cancer (ES‐SCLC) patients with performance status (PS) 2. However, older patients often exhibit poor PS (3, 4), and the treatment effect in th
Externí odkaz:
https://doaj.org/article/734358fe8024448d9b3af96c47a4f54d
Autor:
Kana Kurokawa, Yoichiro Mitsuishi, Naoko Shimada, Naoaki Ito, Misa Ogiwara, Keita Miura, Tetsuhiko Asao, Ryo Ko, Takehito Shukuya, Rina Shibayama, Hiromasa Goto, Kazuhisa Takahashi
Publikováno v:
Thoracic Cancer, Vol 14, Iss 5, Pp 442-449 (2023)
Abstract Background and Aim Immune checkpoint inhibitors have significantly improved the clinical outcomes of many cancer types, but they induce a range of immune‐related adverse events (irAEs). Although adrenal insufficiency (AI) is a rare irAE, i
Externí odkaz:
https://doaj.org/article/e243eed5e31e4d2c83f5d4e095335150
Autor:
Taichi Miyawaki, Hirotsugu Kenmotsu, Kosei Doshita, Hiroaki Kodama, Naoya Nishioka, Yuko Iida, Eriko Miyawaki, Nobuaki Mamesaya, Haruki Kobayashi, Shota Omori, Ryo Ko, Kazushige Wakuda, Akira Ono, Tateaki Naito, Haruyasu Murakami, Keita Mori, Hideyuki Harada, Masahiro Endo, Kazuhisa Takahashi, Toshiaki Takahashi
Publikováno v:
Cancer Medicine, Vol 12, Iss 2, Pp 1451-1460 (2023)
Abstract Background Programmed cell death 1 (PD‐1)/programmed cell death ligand (PD‐L1) inhibitors plus chemotherapy (ICI + Chemo) is the standard treatment for advanced non‐small‐cell lung cancer (NSCLC). However, the impact of tumour burden
Externí odkaz:
https://doaj.org/article/6a37993073c9463ea5acbdf407d85511